

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Food Funct.*, 2022, **13**, 3381

Beneficial effects of eugenol supplementation on gut microbiota and hepatic steatosis in high-fat-fed mice

Marina Rodrigues, ^{*a} Caroline Bertoncini-Silva, ^a
Anderson Gregorio Joaquim, ^a Cássia Dias Machado,^a
Leandra Náira Zambelli Ramalho,^b Daniela Carlos,^c Priscila Giacomo Fassini^a and
Vivian Marques Miguel Suen^a

Due to the increase in the prevalence of obesity, new therapies have emerged and eugenol has been shown to be beneficial in metabolic changes and gut microbiota. This study aimed to investigate the effects of eugenol on gut microbiota, hepatic lipid accumulation, body weight, adipose tissue weight, lipid and glycemic profile in mice fed a high-fat diet. Forty C57BL/6 male mice were divided into standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE) and high-fat diet with eugenol (HFDE). The dose used of eugenol was 500 mg kg⁻¹ for 8 weeks. Eugenol did not prevent weight gain, but it was effective in preventing hepatic lipid accumulation evidenced by the presence of fat droplets in the HFD group and absence in the HFDE group. An improvement in the gut microbiota profile was observed, proved by an increase in the Actinobacteria phylum in the treated groups and a reduction of Proteobacteria phylum in the HFDE group. Despite not preventing weight gain, eugenol appeared to have a protective effect on hepatic lipid accumulation and beneficially modulate the gut microbiota in mice fed with HFD.

Received 27th October 2021,
Accepted 3rd February 2022

DOI: 10.1039/d1fo03619j

rsc.li/food-function

1 Introduction

Obesity is a multifactorial chronic disease (CD), characterized by fat accumulation in the adipocytes. Its multifactorial etiology is related to environmental, emotional, genetic, and life-style factors.^{1–3} According to data from the World Health Organization, the number of overweight adults in 2016 was more than 1.9 billion, and over 650 million of them were obese.⁴ Obesity is a serious health problem worldwide and is a risk factor for the emergence of other CD,⁵ such as cardiovascular disease, type 2 diabetes,⁶ cancer, hypertension,^{7,8} respiratory disorders, among others.⁹

Recently, gut microbiota (GM) has been studied for playing an important role in the pathophysiology of obesity. Studies have shown a strong relationship between weight gain/obesity

and the composition of the GM.^{10–13} The GM is composed mainly of seven phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Verrucomicrobia, Fusobacteria, and Cyanobacteria, with Firmicutes and Bacteroidetes being the most abundant species.¹⁰ The imbalance between beneficial and pathogenic bacteria that compose the microbiota is defined as dysbiosis.^{11,14} Lifestyle, diet, immune system, some types of antibiotics, age, and type of delivery are some factors that affect the GM and may contribute to dysbiosis and consequently to the development of many diseases.^{15–17} Studies have shown that the composition of the GM between healthy individuals and individuals with obesity is different, both in humans and in animal models.^{18,19} For example, individuals with obesity have an altered relationship between Bacteroidetes and Firmicutes, characterized by a decrease in the Bacteroidetes phylum and an increase in the Firmicutes phylum, compared to eutrophic individuals.^{11,20}

Among the various treatment possibilities for obesity, unconventional therapies can be mentioned. One of these therapies is herbal medicines, which can contribute to satiety and increase energy metabolism and consequently promote weight loss.²¹ Eugenol is the major bioactive component extracted from clove oil^{22,23} and has anti-inflammatory, antimicrobial, antibacterial, antioxidant, antiviral, anesthetic, anti-

^aDepartment of Internal Medicine, Division of Nutrology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, CEP, 14049-900 Ribeirão Preto, São Paulo, Brazil. E-mail: marina.rnutri@gmail.com

^bDepartment of Pathology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, CEP, 14049-900 Ribeirão Preto, São Paulo, Brazil

^cDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, CEP, 14049-900 Ribeirão Preto, São Paulo, Brazil

tumor, antidiabetic, antiseptic, and insecticide effects.^{23–25} Włodarska *et al.*²⁶ performed a study testing six phytonutrients, including eugenol, to evaluate the mechanism of action and the ability to alter the mucosal immune responses in the intestines of mice. They showed that all phytonutrients promoted changes in the expression of innate immune genes in the colon. However, just eugenol stimulated the production of the inner mucus layer, an important barrier for microbes, suggesting that eugenol acts to strengthen the mucous barrier, which protects against pathogens and invasive diseases.

Therefore, considering the possible effects of eugenol modulating properties of the innate immune system in mouse intestine, and the role of the GM in the pathophysiology of obesity, we explore the effects of eugenol on the modulation of the GM to investigate whether this substance influences the bacterial profile, and verify if any associated changes to GM could be beneficial towards the prevention or treatment of obesity. Thus, this study aimed to investigate the effects of eugenol on gut microbiota, histology of the liver, body and adipose tissue weight in mice fed a high-fat diet.

2 Materials and methods

2.1 Ethics statement

The experimental protocol was approved by the Animal Research Ethics Committee of Ribeirão Preto Medical School, University of São Paulo (protocol number 016/2015-1) and the ethical principles had their origins in the Declaration of Helsinki in the U.K. Animals (Scientific Procedures) and was in accordance with the ARRIVE guidelines.

2.2 Animals and treatment

Forty C57BL/6 male mice, 6–8 weeks old, weighing on average 20 g, were obtained from the Animal Facilities of Ribeirão Preto Medical School of the University of São Paulo, and kept in cages under controlled conditions of 12 h dark-light cycles and constant temperature (25 ± 1 °C) with water and diet *ad libitum*.

The animals were randomly separated into four groups of ten animals each: standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). All groups were fed with an industrialized diet (AIN 93G) and the HFD group received 40% of lipids. The nutritional composition and the ingredients of the standard diet and the high-fat diet are described in Table 1.

Eugenol (97–99% purity) was purchased from Sigma-Aldrich (Ref: E5504). Animals from the SDE and HFDE groups received 500 mg kg⁻¹ of body weight per day of eugenol supplementation with soybean oil as a vehicle by gavage. Groups that did not receive supplementation (SD and HFD), received only soy oil by gavage.

The animals were kept in an adaptation period for 3 weeks (pre-treatment) and received supplementation for 8 weeks (treatment period) thus undergoing 11 weeks of the experiment. They were weighed before the beginning of the experi-

Table 1 Nutritional composition of the standard and high-fat diets^a (g/1000 g diet)

Macronutrients	Standard diet ^b	High-fat diet ^c
Carbohydrates	639.5 g (64%)	483.7 g (41.3%)
Lipids	70 g (15.8%)	207 g (39.8%)
Proteins	203 g (20.3%)	221.8 g (18.9%)
Energy	4000 kcal	4685.2 kcal

^a Source: PragSoluções. ^b Standard diet (AIN 93G), contains the following nutritional composition: 397.5 g corn starch; 200 g casein; 132 g dextrinized starch; 100 g sucrose; 70 g soybean oil; 50 g microcrystalline cellulose; 35 g mineral mix; 10 g vitamin mix; 3 g L-cystine; 2.5 g choline bitartrate; 0.014 g BHT. ^c High-fat diet (AIN 93 HF 40%), contains the following nutritional composition: 273.7 g corn starch; 220 g casein; 100 g dextrinized starch; 100 g sucrose; 40 g soybean oil; 167 g lard; 50 g microcrystalline cellulose; 35 g mineral mix; 10 g vitamin mix; 1.8 g L-cystine; 2.5 g choline bitartrate; 0.014 g BHT.

ment and weekly thereafter using a digital scale with a maximum capacity of 15 kg (Filizola S.A., São Paulo, Brazil).

At the end of the experiment, the animals were euthanized by decapitation and blood samples were collected and promptly centrifuged at 3500 rpm, 4 °C for 15 min to obtain the serum, which was kept in a freezer at -70 °C for subsequent biochemical analysis. During the sacrifice, samples of hepatic tissue, pancreas, epididymal, retroperitoneal, and brown adipose tissue were collected and weighed. Liver fragments were separated and fixed in 10% buffered formalin for 48 h and embedded in paraffin for histological analysis. Stool samples were collected for gut microbiota analysis and stored in a freezer at -70 °C until the analysis.

2.3 Glucose tolerance test (GTT)

The glucose tolerance test followed a previously standardized methodology.^{27,28} It was performed after a 10 h fasting period, along with the first blood collection (time 0) by a cut at the caudal end of the animal. Subsequently, a glucose solution of 1 mg g⁻¹ of the animal's weight was injected intraperitoneally. Blood collection was performed at times 0', 30', 60', and 120'. Glucose concentrations were determined by the Accu-Chek glucometer (Accu-chek Performa Roche, Mannheim, Germany) according to the manufacturer's specifications.

2.4 Biochemical analysis

Insulin analysis was performed by the commercial Elisa Ultrasensitive Kit (Mouse Ultrasensitive Insulin ELISA, Alpcos Diagnostics, Salem USA). Total cholesterol, triglycerides and HDL were analyzed by enzymatic method using commercial kits from Labtest (Labtest Diagnóstica S.A., Brazil).^{27,28}

2.5 Histological analysis

Formalin-fixed and paraffin-embedded tissue sections were cut to a thickness of 5 µm and stained with hematoxylin and eosin for histological examination. A pathologist who was blinded for the treatment used light microscopy to evaluate liver histological alterations, such as steatosis and the degree of changes:²⁷ absence of change, mild, moderate, and severe



changes. The analysis was performed on 10 randomly chosen high-power fields (HPFs; $\times 40$ magnification) in each slide.

2.6 Gut microbiota analysis

To evaluate the relative abundance of phyla in the gut microbiota, a simple fecal collection of fecal pellets was performed, located at the end of the intestine (rectum). The tweezer used to collect these samples was exclusive and separated from the other materials. Fecal samples, were frozen at -70°C until phylum quantitative PCR (q-PCR) analysis.

Fecal DNA was obtained using the DNeasy® PowerSoil® kit (Qiagen, Hilden, Germany). Relative abundance of bacteria from the Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria phyla was determined using universal primers for the 16S rRNA gene (Eubacteria) or specific for the different phyla.

The primer sequences are described in Table 2.²⁹ The differences (ΔCT) between the cycle threshold (CT) values of Eubacteria and specific bacterial groups were used to obtain normalized levels of each bacterial group ($2^{-\Delta\text{CT}}$). The relative abundance of each bacterial group was obtained after normalization with the control groups.

2.7 Statistical analysis

Sample size was determined using previous experimental studies for metabolic assessment. All data are presented as mean and standard derivation. The Kolmogorov–Smirnov test was adopted to identify the normality of the data. All statistical analyses were performed using a one-way ANOVA, followed by *post hoc* Tukey's test for multiple comparisons and to identify

differences between groups. Data analysis was performed using the IBM SPSS version 22 software. A significance level of 5% was adopted.

3 Results

3.1 Effects of eugenol on body weight and food intake in experimental groups

No difference was observed for the initial weight among the groups. The final weight and, consequently, the percentage of weight gain were higher in the HFDE group when compared with the SDE group. Relative to food intake, a significant difference was observed between the HFD group when compared to the SD group, since the HFD group presented lower food intake than the SD group, but both groups had a similar weight gain, showing the efficacy of high fat diet with higher energy density (Table 3).

3.2 Effect of eugenol on tissue weight in experimental groups

As expected, retroperitoneal and epididymal white adipose tissue weight were significantly higher in HFD groups in comparison with SD groups, showing the effect of a high-fat diet. No difference was observed in the liver, pancreas, and brown adipose tissue weights (Table 4).

3.3 Effect of eugenol on biochemical profile in experimental groups

In order to evaluate the lipid profile, we detected the total cholesterol in serum and observed that in the HFDE group it was significantly higher than in the HFD group (45%, $p < 0.05$). Furthermore, there was a significant increase in the HDL-c in the HFDE group when compared to the HFD group (73%, $p < 0.05$), and regarding triglycerides, the HFD group showed significantly lower values (38%, $p < 0.05$) than the SD group. No significant statistical differences were observed for insulin levels in the serum between the groups (Table 5).

3.4 Effect of eugenol on GTT in experimental groups

As shown in Fig. 1, glycemia was similar in all groups at all time points, except at 30 minutes, when the SD and SDE groups had a 20% lower blood glucose peak; however it was not statistically significant. In a similar manner, the area under the curve was not different between the groups as well.

Table 2 Sequence of primers of interest in this study

Primer	Sequência
Actinobacteria	FP-TGTAGCGGTGGAATGCGC RP-AATTAAGCCACATGCTCCGCT
Bacteroidetes	FP-GTTTAATTCGATGATACGCGAG RP-TTAASCCGACACCTCACGG
Firmicutes	FP-ATGTGGTTTAATTCGAAGCA RP-AGCTGACGACAACCATGCAC
Proteobacteria	FP-CATGACGTTACCCGAGAGAAG RP-CTCTACGAGACTCAAGCTTGC
Eubacteria universal	FP-ACTCCTACGGGAGGCAGCAGT RP-ATTACCGCGGCTGCTGGC

Forward primer (FP), reverse primer (RP). Source: ref. 29.

Table 3 Body weight gain and food intake of mice fed with standard and high-fat diet with and without eugenol

	SD	HFD	SDE	HFDE
Initial weight (g)	20 \pm 1.7	19.5 \pm 1.2	19.7 \pm 0.9	19 \pm 0.8
Final weight (g)	28.8 \pm 1.8	28.4 \pm 2.0	26.7 \pm 1.5	28.8 \pm 1.7 [*]
Weight gain (%)	44.5 \pm 9.4	45.9 \pm 10.2	35.7 \pm 7.2	51.9 \pm 11.6 [*]
Food intake (g per week)	2.39 \pm 0.06	1.91 \pm 0.07 [*]	2.27 \pm 0.07	2.04 \pm 0.11

Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). ^{*}Different from SD, ^{*}different from SDE. All the groups were analyzed by one-way ANOVA followed by Tukey's test ($p < 0.05$). Data are represented as mean \pm standard deviation, $n = 10$ per group.



Table 4 Tissue weight of mice fed with standard and high-fat diet with and without eugenol (analysis at the end of experimental period)

	SD	HFD	SDE	HFDE
Retroperitoneal adipose tissue (g)	0.52 ± 0.27	0.99 ± 0.40*	0.46 ± 0.22	0.74 ± 0.35
Epididymal adipose tissue (g)	1.35 ± 0.63	2.36 ± 0.78*	1.53 ± 0.47	2.24 ± 0.79
Brown adipose tissue (g)	0.34 ± 0.06	0.32 ± 0.08	0.36 ± 0.09	0.33 ± 0.79
Liver (g)	3.97 ± 0.80	3.58 ± 0.44	4.41 ± 0.08	4.13 ± 0.43
Pancreas (g)	0.43 ± 0.09	0.34 ± 0.08	0.42 ± 0.11	0.41 ± 0.07

Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). * Different from SD. All the groups were analyzed by one-way ANOVA followed by Tukey's test ($p < 0.05$). Data are represented as mean ± standard deviation, $n = 10$ per group.

Table 5 Plasma biochemical profile of mice fed with standard and high-fat diet with and without eugenol (analysis at the end of experimental period)

	SD	HFD	SDE	HFDE
HDL cholesterol (mg dL ⁻¹)	84.5 ± 26.8	77.6 ± 14.4	58.6 ± 30.5	101.5 ± 13.8 ^{&}
Total cholesterol (mg dL ⁻¹)	121.8 ± 29.6	123 ± 27.0	144.1 ± 47.4	178.1 ± 28.5 [#]
Triglycerides (mg dL ⁻¹)	90.4 ± 29.2	55.8 ± 7.2*	81.3 ± 28.1	61.2 ± 15.8
Insulin (ng dL ⁻¹)	0.7 ± 0.4	0.7 ± 0.3	0.8 ± 0.5	1.02 ± 0.3

Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). *Different from SD, [#]different from HFD, [&]different from SDE. All the groups were analyzed by one-way ANOVA followed by Tukey's test ($p < 0.05$). Data are represented as mean ± standard deviation, $n = 10$ per group.




Fig. 1 (a) Glucose tolerance test (GTT) of the experimental groups at the different time points. (b) Area under the curve. Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). All the groups were analyzed by one-way ANOVA followed by Tukey's test ($p < 0.05$). Data are represented as mean ± standard deviation, $n = 10$ per group.

3.5 Effect of eugenol on histological analysis of liver in experimental groups

Fig. 2 shows the histological analysis of the liver of animals from different groups. It was observed that the liver of the animals from the HFD group (Fig. 2b) showed the presence of fat droplets (pointed by the arrow), while in the HFDE group these droplets were absent (Fig. 2d), suggesting that eugenol was effective in preventing fat accumulation in the liver of the mice that received a high-fat diet.

3.6 Effect of eugenol on gut microbiota composition in experimental groups

The groups supplemented with eugenol (SDE and HFDE groups) showed an increased relative abundance of the

phyla Firmicutes, Bacteroidetes and Actinobacteria (Fig. 3a, b and c). On the other hand, the HFDE group had lower values of Proteobacteria phylum when compared to the SDE group, indicating that eugenol supplementation reduced this phylum in the gut microbiota induced by HFD (Fig. 3d).

4 Discussion

The present study demonstrated that eugenol supplementation prevented fat accumulation in the liver of the mice fed with a high-fat diet and promoted an increase in the abundance of Actinobacteria phylum and a reduction in the phylum Proteobacteria. On the other hand, eugenol did not prevent






Fig. 2 Histological analysis of the liver. (a) Standard diet (SD); (b) high-fat diet (HFD); (c) standard diet with eugenol (SDE); (d) high-fat diet with eugenol (HFDE). (Hematoxylin and eosin, $\times 40$ magnification).




Fig. 3 Relative abundance of phyla of gut microbiota. (a) Firmicutes; (b) Bacteroidetes; (c) Actinobacteria; (d) Proteobacteria. Fold change (FC). Standard diet (SD); high-fat diet (HFD); standard diet with eugenol (SDE); high-fat diet with eugenol. *Different from SD, #different from HFD, &different from SDE. All the groups were analyzed by one-way ANOVA followed by Tukey's test ($p < 0.05$). Data are represented as mean \pm standard deviation, $n = 10$ per group.

weight gain or increased serum glucose levels, neither increased total cholesterol in mice fed a high-fat diet.

A preliminary study was previously carried out to define the eugenol dose used in the present study. However, the chosen dose is within a non-toxic dose according to De Souza.³⁰

Regarding food intake, we observed a difference between the SD and HFD groups. Our findings agreed with White *et al.*,³¹ and although not significantly, the SD and SDE groups had a higher total food intake. Another study using an aspirin ester with eugenol (AEE) in Wistar rats for 8 weeks found that the



food intake of the HFD and HFD + AEE groups was significantly lower than the SD group, and no difference was observed between the HFD and HFD + AEE groups.³²

The body weight results showed a difference between SDE and HFDE groups, where the HFDE group showed higher weight gain (40%). The SD and HFD groups gained equal weight, which explains the effectiveness of the diet since the HFD group had a lower food intake and gained more weight. This fact is due to the higher energy density of the high-fat diet. Our results differed from Jung *et al.* and Ding *et al.*, where clove supplementation associated with HFD promoted less body weight gain when compared to HFD only.^{33,34} In this context, Harb *et al.* used two different doses of eugenol (10 mg and 100 mg per kg of body weight) in Wistar rats fed a hypercholesterolemic diet (HCD) and standard diet (SD) for 4 weeks. In contrast to the current study, all groups started the experiment with similar body weight, but animals from HCD and HCD + eugenol 100 mg groups gained less weight when compared to those of the SD group.³⁵

After analyzing the tissue weight, no differences were found for the liver weight. Our findings diverge from previous studies, since Jung *et al.* and Ding *et al.* observed lower liver weight for the high-fat diet treated group compared to the untreated group.^{33,34} Another study supplemented eugenol in C57BL/6J mice fed HFD for 12 weeks and found that eugenol significantly reduced liver weight compared to the untreated HFD group.³⁶ These controversial results can be explained by the time of treatment of our study, which was shorter than of other studies. Later, Harb *et al.* concluded that the groups fed with HCD and HCD + eugenol (10 mg and 100 mg) had a higher liver weight than the SD group, and the HCD + eugenol 10 mg group had a significantly lower liver weight than the HCD group.³⁵

For adipose tissue weight, Jung *et al.* and Ding *et al.* showed that the epididymal adipose tissue weight in the HFD group with clove extract supplementation was significantly lower than the HFD group.^{33,34} Notably, White *et al.* showed that the epididymal and retroperitoneal adipose tissue weight were higher in the HFD group when compared to the SD group,³¹ demonstrating the effectiveness of the diets used.

As far as we know, no study has evaluated the relationship between the weight of brown adipose tissue, retroperitoneal adipose tissue, and the pancreas with eugenol clove oil supplementation. According to our results, eugenol supplementation did not improve the lipid profile. The HFDE group showed higher values of cholesterol and HDL, but the increase in HDL can be explained by the increase in total cholesterol. The literature shows opposing results for lipid profile.^{33,34} Elbahy; Madkour; Abdel-Raheem conducted a study in hyperlipidemic rats showing that the administration of 250 mg kg⁻¹ of eugenol was beneficial for the lipid profile, with a significant reduction of total cholesterol and triglycerides in the hyperlipidemic group with eugenol when compared to the group without supplementation.³⁷

It remains unclear why triglyceride levels were lower in the HFD group when compared to the SD group, but in the literature we found the same unexpected results with C57BL/6N mice.³⁸

Harb *et al.* also confirmed the effect of eugenol as hypolipidemic, and the authors suggested that this effect is mediated in part by the potential transient vanilloid receptor 1 (TRPV1). TRPV1 is expressed in tissues, organs, and sensory nerves and is involved in functional regulation in the liver, pancreas, adipose tissue, and also blood vessels.³⁹ The findings showed that TRPV1 expression is positively regulated in the liver of hypercholesterolemic rats; however, the precise molecular mechanism by which eugenol influences TRPV1 is unclear.³⁵ But in fact, activation of TRPV1 signaling promotes accumulation of fat, while inhibiting this signaling protects against fat accumulation.⁴⁰

Our study showed no difference in insulin levels among the experimental groups. Jung *et al.* found that insulin levels in the HFD group were higher than in HFD with clove extract supplement, suggesting that the increased levels were reduced with supplementation.³³ Therefore, our findings do not agree with this previous result. Another study by Srinivasan *et al.*, administered eugenol intragastrical in doses of 2.5 mg, 5 mg, and 10 mg kg⁻¹ in diabetic Wistar rats for 30 days. The authors showed that 10 mg supplementation promoted a significant reduction in blood glucose levels, an increase in plasma insulin levels, and an improvement in body weight and hepatic glycogen content.⁴¹

Histological analysis demonstrated that eugenol had a possible protective effect on the liver, our findings confirm the results of Jung *et al.*, Ding *et al.*, Harb *et al.*, and Jo *et al.*, who found that eugenol or clove oil supplementation led to reduced fat droplets both in size and number.^{33–36} This effect might be explained by the role played by eugenol in decreasing the accumulation of hepatic lipid by modulating/activating calmodulin dependent protein kinase kinase (CAMKK) – AMP-activated protein kinase (AMPK) – sterol regulatory element-binding protein 1 (SREBP1) signaling pathway, as well as the regulation of lipolysis-related genes such as a cluster of differentiation 36 (CD36), carnitine palmitoyltransferase-1 (CPT-1) and acyl-CoA oxidase (ACO).³⁶

Finally, regarding the gut microbiota profile, eugenol supplementation increased the abundance of the Firmicutes phylum in both HFD and SD groups. This phylum contains more than 250 genera, being considered the largest bacterial phylum. Some of their genera are *Bacillus*, *Lactobacillus*, *Mollicutes*, and *Clostridium*.^{42,43} Although Firmicutes are not considered beneficial due to their capacity to absorb calories from the diet and increase fat storage in the body,³² currently it is already known that within this phylum, some beneficial genera can be found such as *Lactobacillus* with immunomodulatory activity⁴⁴ and *Clostridium leptum* with anti-inflammatory actions.⁴⁵ Therefore, the exact bacterial species that make up this phylum must be better analyzed. In Bacteroidetes phylum, eugenol supplementation also increased the abundance of its groups. This phylum similarly to Firmicutes, can also have beneficial or harmful effects. Beneficially, it can play a role in the prevention of obesity and preventing colonization of the gastrointestinal tract by pathogenic agents, but on the other hand, it can also act as pathogenic and be involved in serious diseases and infections.⁴⁶



In the third phylum analyzed, Actinobacteria, it was observed that supplementation also increased the abundance in the groups without eugenol, which does not agree with Ma *et al.*, who found that the HFD and HFD with AEE groups decreased the abundance of Actinobacteria.³² This Gram-positive phylum, has a large diversity and many beneficial species with probiotic potential. It is divided into six classes: *Actinobacteria*, *Acidimicrobiia*, *Coriobacteriia*, *Nitrospirillum*, *Rubrobacteria*, and *Thermoleophilum*,^{47,48} which together with the Proteobacteria represent only 10% of relative abundance in our gut microbiota. Although groups of Actinobacteria phylum represent a small percentage, they are essential in the development and maintenance of intestinal homeostasis. This phylum is supposed to be involved in the modulation of intestinal permeability, metabolism, immune system, and the gut–brain axis. In addition, some bacterial genera, especially *Bifidobacterium*, play a modulating and therapeutic role in intestinal diseases such as irritable bowel syndrome, colorectal cancer, ulcerative colitis, among others, and also in extra-intestinal diseases, non-alcoholic liver steatosis, depression, respiratory pathologies, psoriasis, among others.⁴⁹ Other beneficial effects of this phylum are being sources of new antibiotics, antifungals, and anticancer agents.⁴⁷

The last analyzed phylum, Proteobacteria, was increased in the SDE group when compared to the SD group, and it was the only phylum whose abundance was reduced by eugenol supplementation in HFD even without a statistical difference. This may suggest a beneficial result since Proteobacteria has been recognized as producing metabolic endotoxemia (ME), that is, a change in permeability due to increased lipopolysaccharides (LPS).⁵⁰ This ME drives the inflammatory process, triggers weight gain and can lead to diabetes onset.⁵¹ Besides, this phylum has also been associated with inflammation of the airways and the increase in its abundance causes an ecological imbalance, leading to greater severity of bronchiectasis.⁵²

In addition to these harmful effects, according to some authors, Proteobacteria may represent a “microbial signature” of disease⁵³ and also is considered as pathogenic with inflammatory potential, which may be the source of increased LPS levels in the visceral adipose tissue,⁵⁴ and the proliferation of this phylum in the gut is associated with dysbiosis or reduced diversity of the intestinal microbial community.⁵⁵

These Gram-negative bacteria, have the largest phylogenetic composition (116 bacterial families), and the phylum is divided into 6 classes: *Alphaproteobacteria*, *Betaproteobacteria*, *Gammaproteobacteria*, *Deltaproteobacteria*, *Epsilonproteobacteria*, and *Zetaproteobacteria*.^{53,55} To our knowledge, no further studies were found investigating eugenol and/or clove oil supplementation in mice fed with HFD. However, the antimicrobial activity of eugenol is already well established in the literature,^{24,25,56,57} although there are no studies that relate it to the gut microbiota of obese animals and/or humans. Therefore, more studies are required to elucidate the possible mechanisms involved in this outcome.

The limitations of the present study are related to the difficulty in finding studies with eugenol itself; therefore, those who administered clove extract were also used to discuss some

variables. Another important limitation was regarding the dose administered. Despite being proved to be within a safe and non-toxic dosage, Harb *et al.* showed that eugenol in lower doses exhibited greater efficacy and better results in body and liver weight, and lipid profile using doses of eugenol at 10 mg and 100 mg associated with HFD in only 4 weeks of treatment.³⁵

5 Conclusion

Eugenol supplementation appeared to prevent liver fat accumulation in the HFDE group. Besides, eugenol supplementation seemed to improve the profile of gut microbiota by promoting both an increase in the Actinobacteria phylum and a reduction in the phylum Proteobacteria. On the other hand, it did not promote beneficial effects related to metabolic profile or weight gain prevention in mice fed a high-fat diet. The implication of these findings on humans still needs to be investigated in further research.

Abbreviations

ACO	Acyl-CoA oxidase
AEE	Aspirin ester with eugenol
AMPK	AMP-activated protein kinase
ANOVA	Analysis of variance
AUC	Area under the curve
CAMKK	Calmodulin dependent protein kinase kinase
CD	Chronic disease
CD36	Cluster of differentiation 36
CPT-1	Carnitine palmitoyltransferase-1
CT	Cycle threshold
FC	Fold change
FP	Forward primer
GM	Gut microbiota
GTT	Glucose tolerance test
HCD	Hypercholesterolemic diet
HFD	High-fat diet
HFDE	High-fat diet with eugenol
ME	Metabolic endotoxemia
RP	Reverse primer
SD	Standard diet
SDE	Standard diet with eugenol
SE	Standard error
SREBP1	Sterol regulatory element-binding protein 1
TRPV1	Transient receptor potential cation channel subfamily V member 1

Ethics statements

All mice experiments were performed in accordance with the ARRIVE guidelines and the ethical principles had their origins in the Declaration of Helsinki in the U.K. Animals (Scientific Procedures).



Author contributions

Marina Rodrigues: conceptualization, methodology, formal analysis, investigation, writing – original draft, writing – review and editing, visualization, project administration, funding acquisition. Caroline Bertoni-Silva: methodology, writing – original draft, writing – review and editing, visualization. Anderson Gregorio Joaquim: formal analysis. Cássia Dias Machado: methodology. Leandra Náira Zambelli Ramalho: resources. Daniela Carlos: resources. Priscila Giacomo Fassini: writing – review & editing. Vivian Marques Miguel Suen: conceptualization, methodology, writing – original draft, writing – review and editing, project administration.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We thank Deisy M. da Silva for assistance with histological analyses and Jefferson Barbosa Guimarães for the assistance with lipid profile and gut microbiota. This work was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

References

- 1 A. R. O. Pinheiro, S. F. T. Freitas and A. C. T. Corso, Uma abordagem epidemiológica da obesidade, *Rev. Nutr.*, 2004, **17**, 523–533, DOI: 10.1590/S1415-52732004000400012.
- 2 Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica, Diretrizes brasileiras de obesidade 4 edn, 2016. Available in: <https://abeso.org.br/wp-content/uploads/2019/12/Diretrizes-Download-Diretrizes-Brasileiras-de-Obesidade-2016.pdf>.
- 3 E. N. Wanderley and V. A. Ferreira, Obesidade: uma perspectiva plural, *Cien. Saude Colet.*, 2010, **15**, 185–194, DOI: 10.1590/S1413-81232010000100024.
- 4 World Health Organization, *Obesity and overweight*, 2020. Available in: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
- 5 R. L. Soeiro, G. S. C. Valente, E. A. Cortez, L. M. Mesquita, S. C. M. Xavier and B. M. I. S. Lobo, Educação em saúde em grupo no tratamento de obesos grau III: Um desafio para os profissionais de saúde, *Rev. Bras. Educ. Med.*, 2019, **43**, 681–691, DOI: 10.1590/1981-5271v43suplemento1-20190005..
- 6 N. Steckhan, C. D. Hohmann, C. Kessler, G. Dobos, A. Michalsen and H. Cramer, Effects of different dietary approaches on inflammatory markers in patients with metabolic syndrome: A systematic review and meta-analysis, *Nutrition*, 2016, **32**, 338–348, DOI: 10.1016/j.nut.2015.09.010.
- 7 J. K. Sethi and A. J. Vidal-Puig, Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation, *J. Lipid Res.*, 2007, **48**, 1253–1262, DOI: 10.1194/jlr.R700005-JLR200.
- 8 A. B. Mariath, L. P. Grillo, R. O. da Silva, P. Schmitz, I. C. de Campos, J. R. P. Medina and R. M. Kruger, Obesidade e fatores de risco para o desenvolvimento de doenças crônicas não transmissíveis entre usuários de unidade de alimentação e nutrição, *Cad. Saúde Pública*, 2007, **23**, 897–905, DOI: 10.1590/S0102-311X2007000400017.
- 9 P. Kopelman, Health risks associated with overweight and obesity, *Obes. Rev.*, 2007, **1**, 13–17, DOI: 10.1111/j.1467-789X.2007.00311.x.
- 10 E. Lau, D. Carvalho, C. Pina-Vaz, J. A. Barbosa and P. Freitas, Beyond gut microbiota: Understanding obesity and type 2 diabetes, *Hormones*, 2015, **14**, 358–369, DOI: 10.14310/horm.2002.1571.
- 11 N. Arslan, Obesity, fatty liver disease and intestinal microbiota, *World J. Gastroenterol.*, 2014, **20**, 16452–16463, DOI: 10.3748/wjg.v20.i44.16452.
- 12 E. Amabebe, F. O. Robert, T. Agbalalah and E. S. F. Orubu, Microbial dysbiosis-induced obesity: Role of gut microbiota in homeostasis of energy metabolism, *Br. J. Nutr.*, 2020, **123**, 1127–1137, DOI: 10.1017/S0007114520000380.
- 13 N. Kobylak, O. Virchenko and T. Falalyeyeva, Pathophysiological role of host microbiota in the development of obesity, *Nutr. J.*, 2016, **15**, DOI: 10.1186/s12937-016-0166-9.
- 14 D. Knights, K. G. Lassen and R. J. Xavier, Advances in inflammatory bowel disease pathogenesis: Linking host genetics and the microbiome, *Gut*, 2013, **62**, 1505–1510, DOI: 10.1136/gutjnl-2012-303954.
- 15 L. Flandroy, T. Poutahidis, G. Berg, G. Clarke, M. C. Dao, E. Decaestecker, E. Furman, T. Haahtela, S. Massart, H. Plovier, Y. Sanz and G. Rook, The impact of human activities and lifestyles on the interlinked microbiota and health of humans and of ecosystems, *Sci. Total Environ.*, 2018, **627**, 1018–1038, DOI: 10.1016/j.scitotenv.2018.01.288.
- 16 S. Sirisinha, The potential impact of gut microbiota on your health: Current status and future challenges, *Asian Pac. J. Allergy Immunol.*, 2016, **34**, 249–264, DOI: 10.12932/AP0803.
- 17 S. M. Jandhyala, R. Talukdar, C. Subramanyam, H. Vuyyuru, M. Sasikala and D. N. Reddy, Role of the normal gut microbiota, *World J. Gastroenterol.*, 2015, **21**, 8787–8803, DOI: 10.3748/wjg.v21.i29.8787.
- 18 R. E. Ley, P. J. Turnbaugh, S. Klein and J. I. Gordon, Human gut microbes associated with obesity, *Nature*, 2006, **444**, 1022–1023, DOI: 10.1038/4441022a.
- 19 R. E. Ley, F. Bäckhed, P. Turnbaugh, C. A. Lozupone, R. D. Knight and J. I. Gordon, Obesity alters gut microbial ecology, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 11070–11075, DOI: 10.1073/pnas.0504978102.
- 20 J. Miyamoto, M. Igarashi, K. Watanabe, S. I. Karaki, H. Mukouyama, S. Kishino, X. Li, A. Ichimura, J. Irie, Y. Sugimoto, T. Mizutani, T. Sugawara, T. Miki, J. Ogawa,



- D. J. Drucker, M. Arita, H. Itoh and I. Kimura, Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids, *Nat. Commun.*, 2019, **10**, 4007, DOI: 10.1038/s41467-019-11978-0.
- 21 L. M. de Freitas Junior and E. B. de Almeida Jr., Medicinal plants for the treatment of obesity: Ethnopharmacological approach and chemical and biological studies, *Am. J. Transl. Res.*, 2017, **9**, 2050–2064.
 - 22 R. Scherer, R. Wagner, M. C. T. Duarte and H. T. Godoy, Composição e atividades antioxidante e antimicrobiana dos óleos essenciais de cravo-da-índia, citronela e palmarosa, *Rev. Bras. Plant. Med.*, 2009, **11**, 442–449, DOI: 10.1590/S1516-05722009000400013.
 - 23 P. Mazzafera, Efeito alelopático do extrato alcoólico do cravo-da-índia e eugenol, *Rev. Bras. Bot.*, 2003, **26**, 231–238, DOI: 10.1590/S0100-84042003000200011.
 - 24 R. S. Affonso, M. N. Rennó, G. B. C. A. Slana and T. C. C. França, Aspectos químicos e biológicos do óleo essencial de cravo da índia, *Rev. Virtual Quim.*, 2012, **4**, 146–161, DOI: 10.5935/1984-6835.20120012.
 - 25 R. A. Oliveira, T. V. Reis, C. K. Sacramento, L. P. Duarte and F. F. Oliveira, Constituintes químicos voláteis de especiarias ricas em eugenol, *Rev. Bras. Farmacogn.*, 2009, **19**, 771–775, DOI: 10.1590/S0102-695X2009000500020.
 - 26 M. Włodarska, B. P. Willing, D. M. Bravo and B. B. Finlay, Phytonutrient diet supplementation promotes beneficial *Clostridia* species and intestinal mucus secretion resulting in protection against enteric infection, *Sci. Rep.*, 2015, **5**, 9253, DOI: 10.1038/srep09253.
 - 27 C. B. Silva, P. G. Fassini, L. N. Z. Ramalho, E. C. da Conceição, A. J. C. M. Zordan, D. Carlos and V. M. M. Suen, Curcuma supplementation in high-fat-fed C57BL/6 mice: No beneficial effect on lipid and glucose profile or prevention of weight gain, *Eur. J. Nutr.*, 2020, **59**, 93–102, DOI: 10.1007/s00394-018-1887-7.
 - 28 A. J. C. M. Zordan, C. B. Silva, A. G. Joaquim, M. Rodrigues, C. D. Machado, D. Carlos, M. C. F. Freitas and V. M. M. Suen, Gingerol supplementation does not change glucose tolerance, lipid profile and does not prevent weight gain in C57BL/6 mice fed a high-fat diet, *Clin. Nutr. Exp.*, 2020, **32**, 11–19, DOI: 10.1016/j.clnex.2020.05.001.
 - 29 M. C. G. Miranda, R. P. Oliveira, L. Torres, S. L. F. Aguiar, N. Pinheiro-Rosa, L. Lemos, M. A. Guimarães, D. Reis, T. Silveira, Ê. Ferreira, T. G. Moreira, D. C. Cara, T. U. Maioli, B. L. Kelsall, D. Carlos and A. M. C. Faria, Frontline Science: Abnormalities in the gut mucosa of non-obese diabetic mice precede the onset of type 1 diabetes, *J. Leukocyte Biol.*, 2019, **106**, 513–529, DOI: 10.1002/JLB.3HI0119-024RR.
 - 30 T. F. S. N. N. De Souza, *Efeito antinociceptivo e antiedematogênico do eugenol*, Dissertação, Universidade Estadual do Ceará, 2007.
 - 31 P. A. S. White, L. M. Cercato, J. M. D. Araújo, L. A. Souza, A. F. Soares, A. P. O. Barbosa, J. M. R. Neto, A. C. Marçal, U. F. Machado, E. A. Camargo, M. R. V. Santos and L. C. Brito, Modelo de obesidade induzida por dieta hiperlipídica e associada à resistência à ação da insulina e intolerância à glicose, *Arq. Bras. Endocrinol. Metabol.*, 2013, **57**, 339–345, DOI: 10.1590/S0004-27302013000500002.
 - 32 N. Ma, X. W. Liu, X. J. Kong, S. H. Li, Z. H. Jiao, Z. Qin, Y. J. Yang and J. Y. Li, Aspirin eugenol ester regulates cecal contents metabolomic profile and microbiota in an animal model of hyperlipidemia, *BMC Vet. Res.*, 2018, **14**, 405, DOI: 10.1186/s12917-018-1711-x.
 - 33 C. H. Jung, J. Ahn, T. I. Jeon, T. W. Kim and T. Y. Ha, *Syzygium aromaticum* ethanol extract reduces high-fat diet-induced obesity in mice through downregulation of adipogenic and lipogenic gene expression, *Exp. Ther. Med.*, 2012, **4**, 409–414, DOI: 10.3892/etm.2012.609.
 - 34 Y. Ding, Z. Gu, Y. Wang, S. Wang, H. Chen, H. Zhang, W. Chen and Y. Q. Chen, Clove extract functions as a natural fatty acid synthesis inhibitor and prevents obesity in a mouse model, *Food Funct.*, 2017, **8**, 2847–2856, DOI: 10.1039/c7fo00096k.
 - 35 A. A. Harb, Y. K. Bustanji, I. M. Almasri and S. S. Abdalla, Eugenol reduces ldl cholesterol and hepatic steatosis in hypercholesterolemic rats by modulating TRPV1 receptor, *Sci. Rep.*, 2019, **9**, 14003, DOI: 10.1038/s41598-019-50352-4.
 - 36 H. K. Jo, G. W. Kim, K. J. Jeong, D. Y. Kim and S. H. Chung, Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6 K signaling pathway, *Biol. Pharm. Bull.*, 2014, **37**, 1341–1351, DOI: 10.1248/bpb.b14-00281.
 - 37 D. A. Elbahi, H. I. Madkour and M. H. Abdel-Raheem, Evaluation of antihyperlipidemic activity of eugenol in triton induced hyperlipidemia in rats, *Int. J. Res. Stud. Biosci.*, 2015, **3**, 19–26.
 - 38 C. Podrini, E. L. Cambridge, C. J. Lelliott, D. M. Carragher, J. Estabel, A. K. Gerdin, N. A. Karp, C. L. Scudamore, Sanger Mouse Genetics Project, R. Ramirez-Solis and J. K. White, High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice, *Mamm. Genome*, 2013, **24**, 5–6, DOI: 10.1007/s00335-013-9456-0.
 - 39 P. Wang, D. Liu and Z. Zhu, Transient Receptor Potential Vanilloid Type-1 Channel in Cardiometabolic Protection, *J. Korean Soc. Hypertens.*, 2011, **17**, 37–47, DOI: 10.5646/jksh.2011.17.2.37.
 - 40 A. L. Motter and G. P. Ahern, TRPV1-null mice are protected from diet-induced obesity, *FEBS Lett.*, 2008, **582**, 2257–2262, DOI: 10.1016/j.febslet.2008.05.021.
 - 41 S. Srinivasan, G. Sathish, M. Jayanthi, J. Muthukumar, U. Muruganathan and V. Ramachandran, Ameliorating effect of eugenol on hyperglycemia by attenuating the key enzymes of glucose metabolism in streptozotocin-induced diabetic rats, *Mol. Cell. Biochem.*, 2014, **385**, 159–168, DOI: 10.1007/s11010-013-1824-2.
 - 42 M. Bajzer and R. J. Seeley, Physiology: obesity and gut flora, *Nature*, 2006, **444**, 1009–1010, DOI: 10.1038/4441009a.
 - 43 H. Tilg, A. R. Moschen and A. Kaser, Obesity and the microbiota, *Gastroenterologia*, 2009, **136**, 1476–1483, DOI: 10.1053/j.gastro.2009.03.030.



- 44 J. O'Callaghan and P. W. O'Toole, Lactobacillus: host-microbe relationships, *Curr. Top. Microbiol. Immunol.*, 2013, **358**, 119–154, DOI: 10.1007/82_2011_187.
- 45 J. Kabeerdoss, V. Sankaran, S. Pugazhendhi and B. S. Ramakrishna, Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India, *BMC Gastroenterol.*, 2013, **13**, DOI: 10.1186/1471-230X-13-20.
- 46 H. M. Wexler, Bacteroides: The good, the bad, and the nitty-gritty, *Clin. Microbiol. Rev.*, 2007, **20**, 593–621, DOI: 10.1128/CMR.00008-07.
- 47 E. A. Barka, P. Vatsa, L. Sanchez, N. Gaveau-Vaillant, C. Jacquard, H.-P. Klenk, C. Clément, Y. Ouhdouch and G. P. V. Wezel, Taxonomy, Physiology, and Natural Products of Actinobacteria, *Microbiol. Mol. Biol. Rev.*, 2015, **80**, 1–43, DOI: 10.1128/MMBR.00019-15.
- 48 B. Gao and R. S. Gupta, Phylogenetic framework and molecular signatures for the main clades of the phylum Actinobacteria, *Microbiol. Mol. Biol. Rev.*, 2012, **76**, 66–112, DOI: 10.1128/MMBR.05011-11.
- 49 C. Binda, L. R. Lopetuso, G. Rizzatti, G. Gibiino, V. Cennamo and A. Gasbarrini, Actinobacteria: A relevant minority for the maintenance of gut homeostasis, *Dig. Liver Dis.*, 2018, **50**, 421–428, DOI: 10.1016/j.dld.2018.02.012.
- 50 C. J. Chang, C. S. Lin, C. C. Lu, J. Martel, Y. F. Ko, D. M. Ojcius, S. F. Tseng, T. R. Wu, Y. Y. Chen, J. D. Young and H. C. Lai, Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota, *Nat. Commun.*, 2015, **6**, DOI: 10.1038/ncomms8489.
- 51 P. D. Cani, J. Amar, M. A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A. M. Neyrinck, F. Fava, K. M. Tuohy, C. Chabo, A. Waget, E. Delmée, B. Cousin, T. Sulpice, B. Chamontin, J. Ferrières, J. F. Tanti, G. R. Gibson, L. Casteilla, N. M. Delzenne, M. C. Alessi and R. Burcelin, Metabolic endotoxemia initiates obesity and insulin resistance, *Diabetes*, 2007, **56**, 1761–1772, DOI: 10.2337/db06-1491.
- 52 W. J. Guan, J. J. Yuan, H. M. Li, Y. H. Gao, Y. Huang, C. L. Chen, R. C. Chen and N. S. Zhong, Proteobacteria community compositions correlate with bronchiectasis severity, *Int. J. Tuberc. Lung Dis.*, 2018, **22**, 1095–1105, DOI: 10.5588/ijtld.18.0037.
- 53 G. Rizzatti, L. R. Lopetuso, G. Gibiino, C. Binda and A. Gasbarrini, Proteobacteria: A Common Factor in Human Diseases, *BioMed Res. Int.*, 2017, DOI: 10.1155/2017/9351507.
- 54 M. M. Pérez, L. M. S. Martins, M. S. Dias, C. A. Pereira, J. A. Leite, E. C. S. Gonçalves, P. Z. de Almeida, E. N. de Freitas, R. C. Tostes, S. G. Ramos, M. R. de Zoete, B. Ryffel, J. S. Silva and D. Carlos, Interleukin-17/interleukin-17 receptor axis elicits intestinal neutrophil migration, restrains gut dysbiosis and lipopolysaccharide translocation in high-fat diet-induced metabolic syndrome model, *Immunology*, 2019, **156**, 339–355, DOI: 10.1111/imm.13028.
- 55 N.-R. Shin, T. W. Whon and J.-W. Bae, Proteobacteria: microbial signature of dysbiosis in gut microbiota, *Trends Biotechnol.*, 2015, **33**, 496–503, DOI: 10.1016/j.tibtech.2015.06.011.
- 56 S. M. Nejad, H. Özgüneş and N. Başaran, Pharmacological and Toxicological Properties of Eugenol, *Turk. J. Pharm. Sci.*, 2017, **14**, 201–206, DOI: 10.4274/tjps.62207.
- 57 S. M. Ali, A. A. Khan, I. Ahmed, M. Musaddiq, K. S. Ahmed, H. Polasa, L. V. Rao, C. M. Habibullah, L. A. Sechi and N. Ahmed, Antimicrobial activities of eugenol and cinnamaldehyde against the human gastric pathogen Helicobacter pylori, *Ann. Clin. Microbiol. Antimicrob.*, 2005, **4**, DOI: 10.1186/1476-0711-4-20.

